ALAMEDA, Calif. — Alveo Technologies Inc. announces that it has received an agreement issued by the U.S. Centers for Disease Control and Prevention (CDC) on a competitive basis to develop a rapid, molecular, point of need diagnostic to detect and differentiate between Influenza A + B, and A/H5 in humans.
In June, CDC issued an open call for innovative solutions to meet CDC’s diagnostic test development needs for avian influenza, the company noted. The virus has been confirmed in birds, cattle, poultry, and people in the United States, heightening the urgency to support advanced preparedness in the event human. . .
Register or Login to keep reading
Thank you for your interest in accessing the complete content. To continue reading, please register for free. By registering, you'll gain full access to our valuable resources, updates, and insights.
If you already have an account please Log In.
